Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
about
Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein traffickingThe EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.Using expression and genotype to predict drug response in yeastAssociation of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemiaPharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.The suppressing effects of BTG3 expression on aggressive behaviors and phenotypes of colorectal cancer: An in vitro and vivo study.Recent trends in targeted anticancer prodrug and conjugate design.The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.Genetic variation in drug transporters in ethnic populations.Systematically characterizing and prioritizing chemosensitivity related gene based on Gene Ontology and protein interaction network.Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis.Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.Silencing of Taxol-Sensitizer Genes in Cancer Cells: Lack of Sensitization Effects.High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutationIntegrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy.Recent development in pharmacogenomics: from candidate genes to genome-wide association studies.RLIP76: A novel glutathione-conjugate and multi-drug transporter.Human transporter database: comprehensive knowledge and discovery tools in the human transporter genes.The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.Disruption of the association between drug transporter and actin cytoskeleton abolishes drug resistance in hypertrophic scar.Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.Role of solute carrier transporters in pancreatic cancer: a review.DNA methylation and personalized medicine.Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity.Knockdown of the T-box transcription factor Brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: implications for a new therapeutic principle.Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer.DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines.The ability of hyaluronan fragments to reverse the resistance of C6 rat glioma cell line to temozolomide and carmustine.Microchamber device for detection of transporter activity of adherent cells.Tracing and targeting cancer stem cells: New venture for personalized molecular cancer therapy.The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.The Central Role of Amino Acids in Cancer Redox Homeostasis: Vulnerability Points of the Cancer Redox Code.MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis.Association of -24CT, 1249GA, and 3972CT ABCC2 Gene Polymorphisms with Methotrexate Serum Levels and Toxic Side Effects in Children with Acute Lymphoblastic Leukemia
P2860
Q27011482-E62B292E-FB64-4DC9-A353-0DD9DC877223Q27852536-9BC3329B-B7BC-4733-AFE2-0D350017DB9FQ28476059-B49BC6E9-9769-4E31-B424-869772CFAF5AQ28538292-511D43B9-BE9E-40A1-91E1-89AD4C43FCB8Q31144283-3F748140-CCAF-4A3E-B0EE-8482A295DAD6Q33566932-779C179F-4ACF-4C5C-99CB-C6D1CEA7AC58Q33573762-17A424EA-CC5E-4FD5-A460-2DEC8707F765Q34279067-76ECFBB5-6A52-4FF2-A7F0-B797ADFB1D61Q34292537-90020576-ACC8-476F-9FB1-15327D859216Q34432563-AB6D1691-6E90-47F8-A8D6-454299B996A9Q34729947-6CF1D639-A4F6-4238-9A6A-9718DBA315CFQ35067903-86BD3783-D9DB-4D55-B79A-A8C83A2E01ADQ35818471-F034FB1C-40F6-46D9-8AA7-5F16FA69FE52Q36059727-5368E223-3203-4652-B2A7-F6E905CE0DBDQ36413695-4E0E9147-D269-4815-8B59-19B986E9954DQ36502944-C89E259B-94C7-466D-8124-4E2F9663F00FQ36874335-E27DB990-CED3-4518-8154-4BDC66A5A67EQ37146979-8C41E3A4-D31C-47B9-9EFB-FE6196719B83Q37591678-91090D38-879C-456D-A26C-0AFDD72A647DQ37617635-8708AA13-015B-4662-B244-48A97CA53B15Q37709344-C7273F58-3054-4A8D-8ADD-16DAC821BC58Q37791990-DE563FD3-9BB4-48E7-B123-1159C52F0D07Q38183877-EB3D8E16-5518-4D4A-A12E-31F877B5C90AQ38236028-323A1893-516E-486E-9726-B3CB35510896Q38250428-4285E8FD-A978-41D6-9C20-3B1813676783Q38506522-8185564E-4A18-4682-B85C-D99C88C69BA5Q38613161-2A34E6CA-3280-4086-8801-6B5505B86A34Q38635079-6117DCD6-3AD0-4347-B455-AD8B1CEC101DQ38755728-D237F5F4-306A-46A3-A649-CA8D09BF9CA9Q38903608-1129739A-D4A3-4E60-B50A-82312B4119CEQ38932015-02A5106C-F906-4176-90CA-55C22BFE01E1Q41984835-D7DD2524-6FED-4866-9737-EBA927FEA6C0Q43258268-21F7216B-F081-4AD3-94D6-1D96ABA8AE90Q47808300-4FCB38A3-A03C-4AA4-8C52-4CC92AC742F1Q49369970-025A4DA6-0D04-4DD5-B223-2B5A94847323Q50874052-FDC3CDA2-5FCB-4066-A627-FD0A06A1147FQ58924217-2652E3D0-D7C6-4F77-937F-5BD3E70C115B
P2860
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
@ast
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
@en
type
label
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
@ast
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
@en
prefLabel
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
@ast
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
@en
P1476
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
@en
P2093
Ying Huang
P2888
P304
P356
10.1007/S10555-007-9050-6
P577
2007-03-01T00:00:00Z